These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8839911)

  • 1. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
    Pavlidis N; Hanauske AR; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
    Ann Oncol; 1996 Jul; 7(5):529-31. PubMed ID: 8839911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
    Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
    Verweij J; Aamdal S; Schellens J; Koier I; Lund B
    Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
    Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
    Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
    Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
    Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
    Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
    Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
    Gamucci T; Paridaens R; Heinrich B; Schellens JH; Pavlidis N; Verweij J; Sessa C; Kaye S; Roelvink M; Wanders J; Hanauske A
    Ann Oncol; 2000 Jul; 11(7):793-7. PubMed ID: 10997805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
    J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.
    Schuette W; Blankenburg T; Guschall W; Dittrich I; Schroeder M; Schweisfurth H; Chemaissani A; Schumann C; Dickgreber N; Appel T; Ukena D
    Clin Lung Cancer; 2006 Mar; 7(5):338-43. PubMed ID: 16640806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer.
    Weitz JJ; Marschke RF; Sloan JA; Grill JP; Jett JR; Knost JA; Hatfield AK; Zenk DW; Bate WW; Schaefer PL
    Lung Cancer; 2000 May; 28(2):157-62. PubMed ID: 10717333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
    Davies AM; Ho C; Beckett L; Lau D; Scudder SA; Lara PN; Perkins N; Gandara DR
    J Thorac Oncol; 2009 Jul; 4(7):862-8. PubMed ID: 19494788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
    Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
    Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.